Harrow Inc HROW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HROW is a good fit for your portfolio.
News
-
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
-
Harrow to Attend 2024 ASRS Annual Meeting
-
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
-
Harrow Provides TRIESENCE® Relaunch Update
-
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
-
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
-
Harrow to Present at Two Investor Conferences in May
-
Harrow Announces First Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $24.23
- Day Range
- $23.96–24.90
- 52-Week Range
- $7.60–25.58
- Bid/Ask
- $24.39 / $24.44
- Market Cap
- $864.73 Mil
- Volume/Avg
- 231,051 / 450,523
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.98
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 217
- Website
- https://www.harrow.com
Comparables
Valuation
|
Metric
|
HROW
|
COLL
|
XERS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 6.72 | — |
Price/Book Value | 14.28 | 5.31 | — |
Price/Sales | 5.98 | 2.77 | 2.11 |
Price/Cash Flow | 155.91 | 5.86 | — |
Price/Earnings
HROW
COLL
XERS
Financial Strength
|
Metric
|
HROW
|
COLL
|
XERS
|
|---|---|---|---|
Quick Ratio | 2.52 | 1.10 | 1.71 |
Current Ratio | 3.00 | 1.21 | 2.37 |
Interest Coverage | −0.38 | 2.42 | −1.58 |
Quick Ratio
HROW
COLL
XERS
Profitability
|
Metric
|
HROW
|
COLL
|
XERS
|
|---|---|---|---|
Return on Assets (Normalized) | −7.59% | 19.65% | −16.59% |
Return on Equity (Normalized) | −40.30% | 117.94% | −859.59% |
Return on Invested Capital (Normalized) | −1.23% | 30.09% | −13.80% |
Return on Assets
HROW
COLL
XERS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Pbsbzmzqnz | Jzjnt | $82.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Xqqnnxdwj | Rqvpdq | $75.2 Bil | |||
| Haleon PLC ADR
HLN
| Nrnqhhx | Scjph | $41.4 Bil | |||
| Viatris Inc
VTRS
| Xhkvnln | Yxsj | $14.4 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Dyrqtcz | Jcbjh | $13.7 Bil | |||
| Catalent Inc
CTLT
| Zjnrmng | Nldmvpf | $10.6 Bil | |||
| Perrigo Co PLC
PRGO
| Vxfwbmc | Mlcjz | $3.8 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Mhvlwzh | Kxmtfvr | $3.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Shrcxdj | Fsx | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Wwzvyyjlq | Grrq | $2.7 Bil |